Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis

IMPORTANCE: Progression-free survival (PFS) rate at 6 months has been proposed as a potential surrogate for overall survival (OS) rate at 12 months for immune checkpoint inhibitor (ICI) trials but requires further assessment for validation. OBJECTIVE: To validate 6-month PFS and objective response r...

Descripción completa

Detalles Bibliográficos
Autores principales: Kok, Peey-Sei, Cho, Doah, Yoon, Won-Hee, Ritchie, Georgia, Marschner, Ian, Lord, Sally, Friedlander, Michael, Simes, John, Lee, Chee Khoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489825/
https://www.ncbi.nlm.nih.gov/pubmed/32897371
http://dx.doi.org/10.1001/jamanetworkopen.2020.11809

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489825/
https://www.ncbi.nlm.nih.gov/pubmed/32897371
http://dx.doi.org/10.1001/jamanetworkopen.2020.11809

Ejemplares similares